NZ592283A - Combination of an insulin and the GLP-1 agonist AVE0010 - Google Patents

Combination of an insulin and the GLP-1 agonist AVE0010

Info

Publication number
NZ592283A
NZ592283A NZ592283A NZ59228309A NZ592283A NZ 592283 A NZ592283 A NZ 592283A NZ 592283 A NZ592283 A NZ 592283A NZ 59228309 A NZ59228309 A NZ 59228309A NZ 592283 A NZ592283 A NZ 592283A
Authority
NZ
New Zealand
Prior art keywords
insulin
glp
pharmaceutical composition
diabetes
medicament
Prior art date
Application number
NZ592283A
Other languages
English (en)
Inventor
Ulrich Werner
Barbel Rotthauser
Christopher James Smith
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42077330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ592283(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102008051834A external-priority patent/DE102008051834A1/de
Priority claimed from DE102008053048A external-priority patent/DE102008053048A1/de
Priority claimed from DE102009038210A external-priority patent/DE102009038210A1/de
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NZ592283A publication Critical patent/NZ592283A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ592283A 2008-10-17 2009-10-09 Combination of an insulin and the GLP-1 agonist AVE0010 NZ592283A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102008051834A DE102008051834A1 (de) 2008-10-17 2008-10-17 Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008053048A DE102008053048A1 (de) 2008-10-24 2008-10-24 Kombination von einem Insulin und einem GLP-1-Agonisten
DE102009038210A DE102009038210A1 (de) 2009-08-20 2009-08-20 Kombination von einem Insulin und einem GLP-1-Agonisten
PCT/EP2009/063195 WO2010043566A2 (de) 2008-10-17 2009-10-09 Kombination von einem insulin und einem glp-1-agonisten

Publications (1)

Publication Number Publication Date
NZ592283A true NZ592283A (en) 2012-09-28

Family

ID=42077330

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ592283A NZ592283A (en) 2008-10-17 2009-10-09 Combination of an insulin and the GLP-1 agonist AVE0010

Country Status (39)

Country Link
US (6) US9526764B2 (enExample)
EP (3) EP2349324B1 (enExample)
JP (2) JP5731981B2 (enExample)
KR (3) KR101939557B1 (enExample)
CN (3) CN105396126A (enExample)
AR (1) AR073872A1 (enExample)
AU (1) AU2009305472B2 (enExample)
BR (2) BRPI0920881B1 (enExample)
CA (2) CA2740685C (enExample)
CL (1) CL2011000851A1 (enExample)
CO (1) CO6361944A2 (enExample)
CR (2) CR20170369A (enExample)
CY (1) CY1119952T1 (enExample)
DK (2) DK2349324T3 (enExample)
DO (1) DOP2011000104A (enExample)
EC (1) ECSP11010986A (enExample)
ES (3) ES2650621T3 (enExample)
HK (1) HK1222568A1 (enExample)
HN (1) HN2011001021A (enExample)
HR (2) HRP20171894T1 (enExample)
HU (3) HUE068164T2 (enExample)
IL (2) IL212258A (enExample)
LT (2) LT3228320T (enExample)
MA (1) MA32703B1 (enExample)
MX (2) MX344293B (enExample)
NI (1) NI201100068A (enExample)
NZ (1) NZ592283A (enExample)
PA (1) PA8845901A1 (enExample)
PE (1) PE20120060A1 (enExample)
PL (3) PL2349324T3 (enExample)
PT (3) PT3677275T (enExample)
RS (2) RS56632B1 (enExample)
RU (1) RU2532378C2 (enExample)
SI (2) SI2349324T1 (enExample)
TN (1) TN2011000160A1 (enExample)
TW (1) TWI494121B (enExample)
UY (1) UY32183A (enExample)
WO (1) WO2010043566A2 (enExample)
ZA (1) ZA201102400B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3124632B2 (ja) * 1992-07-28 2001-01-15 株式会社ユニシアジェックス 車両懸架装置
MY152979A (en) 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
BRPI0920881B1 (pt) 2008-10-17 2021-09-21 Sanofi-Aventis Deutschland Gmbh Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo
BR112012000177B1 (pt) * 2009-07-06 2021-06-01 Sanofi-Aventis Deutschland Gmbh Formulação farmacêutica aquosa contendo metionina, processo para sua preparação, uso da mesma e medicamento para tratar diabetes mellitus
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
GB201112607D0 (en) 2011-07-22 2011-09-07 Glaxo Group Ltd Novel compounds
WO2012052391A1 (en) 2010-10-19 2012-04-26 Glaxo Group Limited Polypeptide with jmjd3 catalytic activity
MX2013008484A (es) * 2011-02-02 2013-08-12 Sanofi Aventis Deutschland Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2.
US20120277147A1 (en) * 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP6408998B2 (ja) 2012-12-21 2018-10-17 サノフイＳａｎｏｆｉ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニスト
TWI780236B (zh) * 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
JP6457484B2 (ja) 2013-04-03 2019-01-23 サノフイＳａｎｏｆｉ インスリンの長時間作用型製剤による糖尿病の治療
CA2915413A1 (en) * 2013-06-17 2014-12-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN112957455A (zh) 2014-01-09 2021-06-15 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
EP3091964A1 (en) 2014-01-09 2016-11-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
MA39301A1 (fr) 2014-01-20 2018-01-31 Hanmi Pharmaceutical Co Ltd Insuline à action prolongée et utilisation associée
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EP3206710B1 (en) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Incretin-insulin conjugates
US10017556B2 (en) * 2014-11-21 2018-07-10 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
BR112017012406A2 (pt) 2014-12-12 2018-07-31 Sanofi Aventis Deutschland formulação com relação fixa de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
US10953076B2 (en) * 2016-05-24 2021-03-23 Merck Sharp & Dohme Corp. Insulin receptor partial agonists and GLP-1 analogues
US11179444B2 (en) 2016-06-09 2021-11-23 Amidebio, Llc Glucagon analogs and methods of use thereof
WO2018055539A1 (en) 2016-09-22 2018-03-29 Wockhardt Limited Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue
BR112019005637A2 (pt) 2016-09-23 2019-07-30 Hanmi Pharm Ind Co Ltd análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
TW201821434A (zh) 2016-10-10 2018-06-16 法商賽諾菲公司 製備包含親脂性修飾的離胺酸側鏈的肽的方法
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
WO2018174668A2 (ko) 2017-03-23 2018-09-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
US20210093698A1 (en) * 2019-09-13 2021-04-01 Sanofi Treatment of type 2 diabetes mellitus
WO2021142733A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
JP2023518645A (ja) * 2020-01-16 2023-05-08 上海仁会生物制▲やく▼股▲ふん▼有限公司 Ｇｌｐ－１の投薬レジメン
US11160925B1 (en) * 2021-01-29 2021-11-02 Insulet Corporation Automatic drug delivery system for delivery of a GLP-1 therapeutic

Family Cites Families (401)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB835638A (en) 1956-12-01 1960-05-25 Novo Terapeutisk Labor As Insulin crystal suspensions having a protracted effect
GB840870A (en) 1957-08-03 1960-07-13 Novo Terapeutisk Labor As Improvements in or relating to insulin preparations
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
US3758683A (en) 1971-04-30 1973-09-11 R Jackson Insulin product
GB1554157A (en) 1975-06-13 1979-10-17 Takeda Chemical Industries Ltd Stable insulin preparation for intra nasal administration
US4153689A (en) 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1527605A (en) 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
US4165370A (en) 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
JPS6033474B2 (ja) 1978-05-11 1985-08-02 藤沢薬品工業株式会社 新規なヒアルロニダ−ゼｂｍｐ−８２３１およびその製造法
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
EP0018609B1 (de) 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
JPS55153712A (en) 1979-05-18 1980-11-29 Kao Corp Insulin pharmaceutical preparation and its production
DE3033127A1 (de) 1980-09-03 1982-04-08 Hoechst Ag, 6000 Frankfurt Neue analoga des insulins
US4367737A (en) * 1981-04-06 1983-01-11 George Kozam Multiple barrel syringe
WO1983000288A1 (en) 1981-07-17 1983-02-03 Balschmidt, Per A stable aqueous, therapeutic insulin preparation and a process for preparing it
NL193099C (nl) 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
DE3326472A1 (de) 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
DE3333640A1 (de) 1983-09-17 1985-04-25 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
CA1244347A (en) 1984-05-29 1988-11-08 Eddie H. Massey Stabilized insulin formulations
US4839341A (en) 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
DE3576120D1 (de) 1984-06-09 1990-04-05 Hoechst Ag Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung.
DE3440988A1 (de) 1984-11-09 1986-07-10 Hoechst Ag, 6230 Frankfurt Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
US5008241A (en) 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK113585D0 (da) 1985-03-12 1985-03-12 Novo Industri As Nye peptider
EP0200383A3 (en) 1985-04-15 1987-09-02 Eli Lilly And Company An improved method for administering insulin
US4689042A (en) 1985-05-20 1987-08-25 Survival Technology, Inc. Automatic medicament ingredient mixing and injecting apparatus
DE3526995A1 (de) 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4960702A (en) 1985-09-06 1990-10-02 Codon Methods for recovery of tissue plasminogen activator
US5496924A (en) 1985-11-27 1996-03-05 Hoechst Aktiengesellschaft Fusion protein comprising an interleukin-2 fragment ballast portion
DE3541856A1 (de) 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
DE3636903A1 (de) 1985-12-21 1987-07-02 Hoechst Ag Fusionsproteine mit eukaryotischem ballastanteil
CA1275922C (en) 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
DE3544295A1 (de) 1985-12-14 1987-06-19 Bayer Ag Thermoplastische formmassen mit hoher kriechstromfestigkeit
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
PH23446A (en) 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
ES2053723T3 (es) 1987-02-25 1994-08-01 Novo Nordisk As Nuevos derivados de insulina.
US5034415A (en) 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
DE3726655A1 (de) 1987-08-11 1989-02-23 Hoechst Ag Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
US6875589B1 (en) 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
DE3827533A1 (de) 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
US4923162A (en) 1988-09-19 1990-05-08 Fleming Matthew C Radiation shield swivel mount
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5225323A (en) 1988-11-21 1993-07-06 Baylor College Of Medicine Human high-affinity neurotransmitter uptake system
FI913037A7 (fi) 1988-12-23 1991-06-20 Novo Nordisk As Ihmisen insuliinianalogit
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
EP0471036B2 (en) 1989-05-04 2004-06-23 Southern Research Institute Encapsulation process
US5227293A (en) 1989-08-29 1993-07-13 The General Hospital Corporation Fusion proteins, their preparation and use
GR1005153B (el) 1989-08-29 2006-03-13 The General Hospital Corporation Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους.
US5358857A (en) 1989-08-29 1994-10-25 The General Hospital Corp. Method of preparing fusion proteins
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
ATE164080T1 (de) 1990-05-10 1998-04-15 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
US5397771A (en) 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
CA2038597A1 (en) 1991-03-19 1992-09-20 Jose P. Garzaran A method and a pharmaceutical preparation for treating pain
US5614219A (en) 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
US6468959B1 (en) 1991-12-05 2002-10-22 Alfatec-Pharm Gmbh Peroral dosage form for peptide containing medicaments, in particular insulin
CH682806A5 (de) 1992-02-21 1993-11-30 Medimpex Ets Injektionsgerät.
CH682805A5 (de) 1992-02-24 1993-11-30 Medimpex Ets Anzeigeeinrichtung für ein Injektionsgerät.
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5846747A (en) 1992-03-25 1998-12-08 Novo Nordisk A/S Method for detecting glucagon-like peptide-1 antagonists and agonists
US5253785A (en) 1992-04-02 1993-10-19 Habley Medical Technology Corp. Variable proportion dispenser
ATE148710T1 (de) 1992-12-02 1997-02-15 Hoechst Ag Verfahren zur gewinnung von proinsulin mit korrekt verbundenen cystinbrücken
WO1994014461A1 (en) 1992-12-18 1994-07-07 Eli Lilly And Company Insulin analogs
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5478323A (en) 1993-04-02 1995-12-26 Eli Lilly And Company Manifold for injection apparatus
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE10199011I2 (de) 1993-06-21 2004-10-14 Novo Nordisk As ASP-B28-Insulinkristalle.
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5534488A (en) 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
EP2275089A1 (en) 1993-11-19 2011-01-19 Alkermes Controlled Therapeutics, Inc. Preparation of biodegradable microparticles containing a biologically active agent
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
IT1265271B1 (it) 1993-12-14 1996-10-31 Alcatel Italia Sistema di predistorsione in banda base per la linearizzazione adattativa di amplificatori di potenza
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE4405179A1 (de) 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
DE4405388A1 (de) 1994-02-19 1995-08-24 Hoechst Ag Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen
EP0748213B1 (en) 1994-03-07 2004-04-14 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5559094A (en) 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
PT779806E (pt) 1994-09-09 2001-02-28 Takeda Chemical Industries Ltd Preparacao de libertacao sustentada contendo um sal metalico de um peptido
US5879584A (en) 1994-09-10 1999-03-09 The Procter & Gamble Company Process for manufacturing aqueous compositions comprising peracids
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
YU18596A (sh) 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
AU5724996A (en) 1995-05-05 1996-11-21 Eli Lilly And Company Single chain insulin with high bioactivity
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US6143718A (en) 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
AU6011496A (en) 1995-06-08 1997-01-09 Therexsys Limited Improved pharmaceutical compositions for gene therapy
EP0835101B1 (en) 1995-06-27 2004-06-09 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
JPH11292787A (ja) 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
TR199802789T2 (xx) 1996-06-05 1999-03-22 Boehringer Mannheim Gmbh Eksendin analoglar� bunlar�n �retimi i�in y�ntemler ve bunlar� i�eren farmas�tik m�stahzarlar.
DE19637230A1 (de) 1996-09-13 1998-03-19 Boehringer Mannheim Gmbh Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
PL188736B1 (pl) 1996-06-20 2005-04-29 Novo Nordisk As Wodny preparat insuliny oraz sposób jego przygotowania
KR100451778B1 (ko) 1996-06-20 2004-11-16 노보 노르디스크 에이/에스 Nacl을함유하는인슐린제제
US6110703A (en) 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
CA2262647C (en) 1996-08-08 2007-12-04 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
AU752411B2 (en) 1996-08-13 2002-09-19 Genentech Inc. Formulation
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
DK0944648T3 (da) 1996-08-30 2007-07-02 Novo Nordisk As GLP-1 derivater
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6384016B1 (en) 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE69831673C5 (de) 1997-01-07 2015-01-22 Amylin Pharmaceuticals, Llc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
EP0981611A1 (en) 1997-02-05 2000-03-01 1149336 Ontario Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
US6043214A (en) 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
AU742591B2 (en) 1997-03-20 2002-01-10 Novo Nordisk A/S Zinc free insulin crystals for use in pulmonary compositions
PE79099A1 (es) 1997-06-13 1999-08-24 Lilly Co Eli Formulaciones de insulina estables
CA2292730C (en) 1997-06-13 2008-09-16 Genentech, Inc. Stabilized antibody formulation
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
ES2293688T5 (es) 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
DE19735711C2 (de) 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
HUP0004169A3 (en) 1997-10-24 2001-06-28 Lilly Co Eli Insoluble insulin compositions and process for production thereof
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
WO1999024015A1 (en) 1997-11-12 1999-05-20 Alza Corporation Buffered drug formulations for transdermal electrotransport delivery
JP2003522721A (ja) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト化合物
BR9814189A (pt) 1997-11-14 2000-10-03 Amylin Pharmaceuticals Inc "compostos agonistas da exendina"
CA2312190A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
EP1044016B1 (en) 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
JP4677095B2 (ja) 1998-02-13 2011-04-27 アミリン・ファーマシューティカルズ，インコーポレイテッド エキセンジンおよびｇｌｐ−１の変力および利尿効果
TR200003048T2 (tr) 1998-02-23 2000-12-21 Neurocrine Biosciences, Inc. İnsülinin peptit analoglarının diyabet tedavisi için kullanımı.
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1062229A1 (en) 1998-03-09 2000-12-27 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
ATE413889T1 (de) 1998-06-05 2008-11-15 Nutrinia Ltd Insulin angereichertes säuglingsnährpräparat
AU6294899A (en) 1998-10-07 2000-04-26 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
CN1210058C (zh) 1998-10-16 2005-07-13 诺沃挪第克公司 用于肺送递的稳定的浓缩胰岛素制剂
CA2346884A1 (en) 1998-10-16 2000-04-27 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
ATE259653T1 (de) 1998-11-18 2004-03-15 Novo Nordisk As Stabile wässrige insulinzubereitungen ohne phenol und kresol
ES2244416T5 (es) 1999-01-14 2020-01-03 Amylin Pharmaceuticals Llc Formulaciones novedosas de agonistas de la exendina y métodos de administración de los mismos
DE19908041A1 (de) 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2007204498A (ja) 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6227819B1 (en) 1999-03-29 2001-05-08 Walbro Corporation Fuel pumping assembly
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
BR0010705A (pt) 1999-04-30 2002-02-05 Amylin Pharmaceuticals Inc Exendinas modificadas e agonistas da exendina
ATE252601T1 (de) 1999-05-17 2003-11-15 Conjuchem Inc Lang wirkende insulinotrope peptide
WO2000074736A1 (en) 1999-06-04 2000-12-14 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
EP1196189A2 (en) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
DE19930631A1 (de) 1999-07-02 2001-01-11 Clemens Micheler Spritzvorrichtung zur Injektion mindestens zweier flüssiger Therapeutika, insbesondere Insuline
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
IL148685A0 (en) 1999-09-21 2002-09-12 Rtp Pharma Inc Surface modified particulate compositions of biologically active substances
DE19947456A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
WO2001024814A1 (en) 1999-10-04 2001-04-12 Chiron Corporation Stabilized liquid polypeptide-containing pharmaceutical compositions
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
EP1229918B1 (en) 1999-11-03 2008-03-26 Bristol-Myers Squibb Company Pharmaceutical composition comprising a combination of metformin and glibenclamide
EP1523993A1 (en) 1999-12-16 2005-04-20 Eli Lilly & Company Polypeptide compositions with improved stability
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
CA2394213A1 (en) 1999-12-16 2001-06-21 Eli Lilly And Company Polypeptide compositions with improved stability
US20010012829A1 (en) 2000-01-11 2001-08-09 Keith Anderson Transepithelial delivery GLP-1 derivatives
AU2353701A (en) 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2001093837A2 (en) 2000-06-08 2001-12-13 Eli Lilly And Company Protein powder for pulmonary delivery
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
US20030212248A1 (en) 2000-07-12 2003-11-13 Furman Thomas Charles Process to increase protein stability
EP1970072A1 (en) 2000-09-18 2008-09-17 Sanos Bioscience A/S Use of GLP-2 peptides for the treatment of hyperparathyroidism
KR100508695B1 (ko) 2001-02-13 2005-08-17 한국과학기술연구원 인슐린의 경구투여용 제형과 그의 제조방법
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
DE10108100A1 (de) 2001-02-20 2002-08-29 Aventis Pharma Gmbh Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse
DE10108211A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
DE10108212A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
WO2002067868A2 (en) 2001-02-26 2002-09-06 Millennium Pharmaceuticals, Inc. Methods for the treatment of metabolic disorders, including obesity and diabetes
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
WO2002079250A1 (en) 2001-04-02 2002-10-10 Novo Nordisk A/S Insulin precursors and a process for their preparation
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
US20030026872A1 (en) 2001-05-11 2003-02-06 The Procter & Gamble Co. Compositions having enhanced aqueous solubility and methods of their preparation
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
AU2002318159A1 (en) 2001-06-29 2003-03-03 The Regents Of The University Of California Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
AU2002317599B2 (en) 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
US7238663B2 (en) 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
US6911324B2 (en) * 2001-10-18 2005-06-28 The Regents Of The University Of California Induction of beta cell differentiation in human cells
EP1448222A4 (en) * 2001-10-19 2006-05-17 Lilly Co Eli BIPHASIC MIXTURES OF GLP-1 AND INSULIN
WO2003035028A1 (en) 2001-10-19 2003-05-01 Nektar Therapeutics Modulating charge density to produce improvements in the characteristics of spray-dried proteins
WO2003035051A2 (en) 2001-10-19 2003-05-01 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
HU228934B1 (hu) 2001-11-19 2013-06-28 Novo Nordisk As Eljárás inzulinvegyületek elõállítására
US7396903B2 (en) * 2001-11-19 2008-07-08 Novo Nordisk A/S Process for preparing insulin compounds
US20030170691A1 (en) 2001-12-19 2003-09-11 Millennium Pharmaceuticals, Inc. Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor
US20050014679A1 (en) 2001-12-20 2005-01-20 Beals John Michael Insulin molecule having protracted time action
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
WO2003066084A1 (en) 2002-02-07 2003-08-14 Novo Nordisk A/S Use of glp-1 compound for treatment of critically ill patients
US20100069293A1 (en) 2002-02-27 2010-03-18 Pharmain Corporation Polymeric carrier compositions for delivery of active agents, methods of making and using the same
TWI351278B (en) 2002-03-01 2011-11-01 Nisshin Pharma Inc Agent for preventing and treating of liver disease
WO2003094951A1 (en) 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
ES2360182T3 (es) 2002-05-07 2011-06-01 Novo Nordisk A/S Formulaciones solubles que comprenden insulina monomérica e insulina acilada.
US7115563B2 (en) 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US6844554B2 (en) 2002-06-28 2005-01-18 Instrumentarium Corp. Method and arrangement for determining the concentration of a gas component in a gas mixture
EP1525219B1 (en) * 2002-07-04 2009-05-27 Zealand Pharma A/S Glp-1 and methods for treating diabetes
DE10235168A1 (de) 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
BR0314799A (pt) 2002-09-27 2005-07-26 Market Biosciences Corp Controle glicêmico aperfeiçoado para pré-diabetes e/ou diabetes do tipo ii usando ácido docosahexaenóico
AU2003268621B2 (en) 2002-10-02 2009-01-15 Zealand Pharma A/S Stabilized exendin-4 compounds
US20050209142A1 (en) 2002-11-20 2005-09-22 Goran Bertilsson Compounds and methods for increasing neurogenesis
AU2003280117B2 (en) 2002-11-20 2009-09-10 Newron Sweden Ab Compounds and methods for increasing neurogenesis
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
CN1413582A (zh) 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 盐酸二甲双胍肠溶片及其制备方法
WO2004050115A2 (en) 2002-12-03 2004-06-17 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
GB0309154D0 (en) 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
GB0304822D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
BRPI0408097A (pt) 2003-03-04 2006-02-14 Technology Dev Company Ltd composição de insulina oral e processos para a produção e para o uso da mesma
JP2007523842A (ja) 2003-03-11 2007-08-23 ノボ　ノルディスク　アクティーゼルスカブ 酸安定化されたインスリンを含有する薬学的製剤
US20040186046A1 (en) 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
CA2518776A1 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
PL1633390T3 (pl) 2003-06-03 2012-06-29 Novo Nordisk As Stabilizowane kompozycje farmaceutyczne peptydu glp-1
DE10325567B4 (de) 2003-06-05 2008-03-13 Mavig Gmbh Strahlenschutzanordnung mit separierbarer Umhüllung
CA2542372A1 (en) 2003-08-29 2005-03-10 Centocor, Inc. Method of promoting graft survival with anti-tissue factor antibodies
JP5518282B2 (ja) 2003-09-01 2014-06-11 ノヴォ ノルディスク アー／エス 安定なペプチドの製剤
WO2005023291A2 (en) 2003-09-11 2005-03-17 Novo Nordisk A/S Use of glp1-agonists in the treatment of patients with type i diabetes
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
ATE525083T1 (de) * 2003-11-13 2011-10-15 Novo Nordisk As Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung
US20050201978A1 (en) 2003-11-17 2005-09-15 Lipton James S. Tumor and infectious disease therapeutic compositions
CN1898087A (zh) 2003-12-22 2007-01-17 诺沃挪第克公司 用于储存药物液体的透明、柔性、不可渗透的塑料容器
US20060210614A1 (en) 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
EP1701714A2 (en) 2004-01-07 2006-09-20 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
US20070027063A1 (en) 2004-01-12 2007-02-01 Mannkind Corporation Method of preserving the function of insulin-producing cells
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20070135338A1 (en) 2004-03-31 2007-06-14 Karyn O'neil Human GLP-1 mimetibodies, compositions, methods and uses
CN1960735B (zh) 2004-05-20 2015-07-29 代阿麦迪卡股份有限公司 药物组合在治疗胰岛素抗性中的应用
CN1993138B (zh) 2004-06-01 2010-12-15 阿雷斯贸易股份有限公司 稳定蛋白质的方法
AU2005267289A1 (en) * 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
EP1906991A2 (en) 2004-06-28 2008-04-09 Novo Nordisk A/S Use of glp-1 receptor agonists and/or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i, diabetes type ii and impaired pancreatic beta-cell function
JP2008507280A (ja) 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
DE602005008071D1 (de) 2004-08-13 2008-08-21 Hoffmann La Roche C-terminale modifikation von polypeptiden
DE102004043153B4 (de) 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
US20060073213A1 (en) 2004-09-15 2006-04-06 Hotamisligil Gokhan S Reducing ER stress in the treatment of obesity and diabetes
EP1791554A2 (en) 2004-09-17 2007-06-06 Novo Nordisk A/S Pharmaceutical compositions containing insulin and insulinotropic peptide
JP2006137678A (ja) 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
WO2006051103A2 (en) * 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
EP2494983B1 (en) 2004-11-12 2019-04-24 Novo Nordisk A/S Stable formulations of glp-1
DE102004058306A1 (de) 2004-12-01 2006-07-27 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
SE0402976L (sv) 2004-12-03 2006-06-04 Mederio Ag Medicinsk produkt
CA2592065A1 (en) 2004-12-22 2007-04-26 Centocor, Inc. Glp-1 agonists, compositions, methods and uses
US7879361B2 (en) 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
US20090142338A1 (en) 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
EP1909824B1 (en) 2005-04-08 2011-05-18 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
JP2008536881A (ja) * 2005-04-21 2008-09-11 ガストロテック・ファルマ・アクティーゼルスカブ Ｇｌｐ−１分子と制吐剤との医薬製剤
US8097584B2 (en) 2005-05-25 2012-01-17 Novo Nordisk A/S Stabilized formulations of insulin that comprise ethylenediamine
JP5198261B2 (ja) 2005-06-06 2013-05-15 カムルス エービー Ｇｌｐ−１類似体製剤
JP5416969B2 (ja) 2005-06-27 2014-02-12 ニュートゥリー カンパニー リミテッド メイスリグナンを利用してｐｐａｒにより媒介される疾患を予防及び治療する方法
US20080227847A1 (en) 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
SI3524261T1 (sl) 2005-08-19 2024-02-29 Amylin Pharmaceuticals, Llc Exendin za uporabo pri zdravljenju sladkorne bolezni in zmanjševanju telesne teže
US20090181887A1 (en) 2005-09-08 2009-07-16 Gastrotech Pharma A/S Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
PT1926749E (pt) 2005-09-14 2011-09-29 Sanofi Aventis Deutschland Clivagem de precursores de insulinas por uma variante de tripsina
ATE514435T1 (de) 2005-09-20 2011-07-15 Novartis Pharma Gmbh Verwendung eines dpp-iv-hemmers zur minderung hypoglykämischer ereignisse
WO2007038540A1 (en) 2005-09-26 2007-04-05 Medtronic, Inc. Prosthetic cardiac and venous valves
DE102005046113A1 (de) 2005-09-27 2007-03-29 Sanofi-Aventis Deutschland Gmbh Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
KR101105871B1 (ko) 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
ES2654520T3 (es) 2005-10-11 2018-02-14 Huntington Medical Research Institutes Agentes de formación de imágenes y métodos de uso de los mismos
PT1940243E (pt) 2005-10-24 2011-10-17 Nestec Sa Formulação de fibras alimentares e método de administração
EP1954242A4 (en) 2005-11-30 2012-08-01 Generex Pharm Inc ORALLY ABSORPTED PHARMACEUTICAL FORMULATION AND METHOD OF ADMINISTRATION
US20100029558A1 (en) 2005-12-06 2010-02-04 Bristow Cynthia L Alpha1 proteinase inhibitor peptides methods and use
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
EP1978987B1 (en) 2006-01-05 2014-12-31 University of Utah Research Foundation Methods and compositions related to improving properties of pharmacological agents targeting nervous system
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
US20090324701A1 (en) 2006-01-20 2009-12-31 Diamedica, Inc. Compositions containing (s)-bethanechol and their use in the treatment of insulin resistance, type 2 diabetes, glucose intolerance and related disorders
US20070191271A1 (en) 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
WO2007095288A2 (en) 2006-02-13 2007-08-23 Nektar Therapeutics Methionine-containing protein or peptide compositions and methods of making and using
US7763582B2 (en) 2006-02-21 2010-07-27 University Of Medicine And Dentistry Of New Jersey Localized insulin delivery for bone healing
ES2397659T3 (es) 2006-03-15 2013-03-08 Novo Nordisk A/S Mezclas de amilina e insulina
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
EP2004213A1 (en) 2006-04-03 2008-12-24 Novo Nordisk A/S Glp-1 peptide agonists
CN101454019A (zh) 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
CA2648440A1 (en) 2006-04-13 2007-10-25 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. . Pharmaceutical compositions of hglp-1, exendin-4 and analogs thereof
US20090099064A1 (en) 2006-06-08 2009-04-16 Diabecore Medical Inc., Derivatized insulin oligomers
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
US8900555B2 (en) 2006-07-27 2014-12-02 Nektar Therapeutics Insulin derivative formulations for pulmonary delivery
EP2057188B1 (en) 2006-08-17 2013-07-31 Amylin Pharmaceuticals, LLC Dpp-iv resistant gip hybrid polypeptides with selectable properties
WO2008023050A1 (en) 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
EA200900392A1 (ru) 2006-09-07 2010-06-30 Никомед Гмбх Комбинированное лечение сахарного диабета
BRPI0717098B8 (pt) 2006-09-22 2021-05-25 Novo Nordisk As análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação
WO2008124522A2 (en) 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
WO2008145323A1 (en) 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
EP2167169B2 (de) 2007-06-14 2016-03-09 Sanofi-Aventis Deutschland GmbH Zweikammerkarpule mit aufsatz
CN101678174A (zh) 2007-06-14 2010-03-24 塞诺菲-安万特德国有限公司 双室卡普耳
EP2173407B1 (en) 2007-07-02 2020-02-19 Roche Diabetes Care GmbH A device for drug delivery
US20090324609A1 (en) 2007-08-09 2009-12-31 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
EP2178909B1 (en) 2007-08-13 2015-10-21 Novo Nordisk A/S Rapid acting insulin analogues
CN101366692A (zh) 2007-08-15 2009-02-18 江苏豪森药业股份有限公司 一种稳定的艾塞那肽制剂
GB0717399D0 (en) 2007-09-07 2007-10-17 Uutech Ltd Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
GB0717388D0 (en) 2007-09-07 2007-10-17 Uutech Ltd Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
WO2009033789A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
RS52566B (sr) 2007-11-01 2013-04-30 Merck Serono S.A. Tečne formulacije lh
US8710000B2 (en) 2007-11-08 2014-04-29 Novo Nordisk A/S Insulin derivative
PL2597103T3 (pl) 2007-11-16 2017-04-28 Novo Nordisk A/S Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
CN101444618B (zh) 2007-11-26 2012-06-13 杭州九源基因工程有限公司 含有艾塞那肽的药物制剂
CN102026666B (zh) 2007-12-11 2013-10-16 常山凯捷健生物药物研发（河北）有限公司 促胰岛素肽缀合物制剂
JP5352596B2 (ja) 2008-01-04 2013-11-27 バイオデル， インコーポレイテッド 組織グルコースレベルの関数としてのインスリン放出のためのインスリン製剤
WO2009087082A2 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
MY152979A (en) * 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
RS52106B (sr) 2008-02-08 2012-08-31 Biogenerix Ag Tečni preparat fsh
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
RU2495131C2 (ru) 2008-02-19 2013-10-10 Байокон Лимитид Способ получения рекомбинантного инсулина гларгина
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US8329419B2 (en) 2008-05-23 2012-12-11 Amylin Pharmaceuticals, Llc GLP-1 receptor agonist bioassays
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
CA2726894A1 (en) * 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
EP2346551B1 (en) 2008-08-30 2020-12-16 Sanofi-Aventis Deutschland GmbH Cartridge and needle system therefor
US20100069292A1 (en) 2008-09-02 2010-03-18 Biodel, Inc. Insulin with a basal release profile
US20100068210A1 (en) 2008-09-10 2010-03-18 Ji Junyan A Compositions and methods for the prevention of oxidative degradation of proteins
CN101670096B (zh) 2008-09-11 2013-01-16 杭州九源基因工程有限公司 含有艾塞那肽的药物制剂
MX2011003833A (es) 2008-10-15 2011-06-20 Intarcia Therapeutics Inc Particulas de farmacos altamente concentradas, formulaciones, suspensiones y uso de las mismas.
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
BRPI0920881B1 (pt) 2008-10-17 2021-09-21 Sanofi-Aventis Deutschland Gmbh Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo
JP4959005B2 (ja) 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
JP2009091363A (ja) 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Ｐｔｈの安定化水溶液注射剤
EP3254616B1 (en) 2009-02-04 2021-06-09 Sanofi-Aventis Deutschland GmbH Medical device and method for providing information for glycemic control
CN106177958A (zh) 2009-02-13 2016-12-07 勃林格殷格翰国际有限公司 包含dpp‑4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
WO2010138671A1 (en) 2009-05-28 2010-12-02 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for sleep enhancement
BR112012000177B1 (pt) 2009-07-06 2021-06-01 Sanofi-Aventis Deutschland Gmbh Formulação farmacêutica aquosa contendo metionina, processo para sua preparação, uso da mesma e medicamento para tratar diabetes mellitus
EP2451472A1 (de) 2009-07-06 2012-05-16 Sanofi-Aventis Deutschland GmbH Hitze- und schüttelstabile insulinzubereitungen
WO2011003823A1 (de) 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Langsamwirkende insulinzubereitungen
US8709400B2 (en) 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
PT2459171T (pt) 2009-07-31 2017-08-16 Sanofi Aventis Deutschland Composição de insulina de atuação longa
WO2011017554A2 (en) 2009-08-07 2011-02-10 Mannkind Corporation Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2329848B2 (en) 2009-11-13 2019-06-19 Sanofi-Aventis Deutschland GmbH Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
CA2685638C (en) 2009-11-13 2017-02-28 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
EP2324853B1 (en) 2009-11-13 2015-08-26 Sanofi-Aventis Deutschland GmbH Lixisenatide as add-on to metformin in the treatment of diabetes type 2
US20110118180A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
US20110118178A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
WO2011075623A1 (en) 2009-12-18 2011-06-23 Latitude Pharmaceuticals, Inc. One - phase gel compos ition compri s ing phos pholi pids
EP2359843A1 (en) 2010-01-21 2011-08-24 Sanofi Pharmaceutical composition for treating a metabolic syndrome
BR112012020481A2 (pt) 2010-02-22 2017-01-10 Univ Case Western Reserve método para tratar um paciente, o método compreendendo administrar uma formulação farmacêutica contendo uma quantidade fisiologicamente efetiva de um análogo de insulina ou um sal fisiologicamente.
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
AR080884A1 (es) 2010-04-14 2012-05-16 Sanofi Aventis Conjugados de insulina-sirna
US8637458B2 (en) 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2011144674A2 (en) 2010-05-20 2011-11-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
US9085757B2 (en) 2010-06-17 2015-07-21 Regents Of The University Of Minnesota Production of insulin producing cells
US8532933B2 (en) 2010-06-18 2013-09-10 Roche Diagnostics Operations, Inc. Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
WO2012012352A2 (en) 2010-07-19 2012-01-26 Amidebio, Llc Modified peptides and proteins
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
KR20130139297A (ko) 2010-10-27 2013-12-20 노보 노르디스크 에이/에스 다양한 주사 간격으로 투여된 인슐린 주사를 이용한 진성 당뇨병의 치료
WO2012065996A1 (en) 2010-11-15 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN
WO2012066086A1 (en) 2010-11-17 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN
JP2013545782A (ja) 2010-12-14 2013-12-26 ノヴォ ノルディスク アー／エス 長時間作用型インスリンと組み合わせた速効型インスリン
MX2013008484A (es) 2011-02-02 2013-08-12 Sanofi Aventis Deutschland Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2.
PL3556774T3 (pl) 2011-03-11 2024-07-01 Beth Israel Deaconess Medical Center Inc. Przeciwciała anty-cd40 i ich zastosowania
US20120277147A1 (en) 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US20130040878A1 (en) 2011-05-13 2013-02-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in the treatment of diabetes type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
MX362527B (es) 2011-05-13 2019-01-23 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
US8735349B2 (en) 2011-05-13 2014-05-27 Sanofi-Aventis Deutschland Gmbh Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
US20140220134A1 (en) 2011-06-24 2014-08-07 Astrazeneca Pharamceuticals LP Method for treating diabetes with extended release formulation of glp-1 receptor agonists
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
WO2013050378A1 (en) 2011-10-04 2013-04-11 Sanofi-Aventis Deutschland Gmbh Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
ES2562651T3 (es) 2011-10-04 2016-03-07 Sanofi-Aventis Deutschland Gmbh Lixisenatida para el uso en el tratamiento de la estenosis o/y la obstrucción del sistema de conductos pancreáticos
CA2851690C (en) 2011-10-28 2022-07-26 Sanofi-Aventis Deutschland Gmbh Treatment protocol of diabetes type 2
US8901484B2 (en) 2012-04-27 2014-12-02 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
US9522235B2 (en) 2012-05-22 2016-12-20 Kaleo, Inc. Devices and methods for delivering medicaments from a multi-chamber container
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
GB201303771D0 (en) 2013-03-04 2013-04-17 Midatech Ltd Nanoparticles peptide compositions
CA2915413A1 (en) 2013-06-17 2014-12-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TW201605489A (zh) 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物
BR112017012406A2 (pt) 2014-12-12 2018-07-31 Sanofi Aventis Deutschland formulação com relação fixa de insulina glargina/lixisenatida
US20160235818A1 (en) 2015-01-16 2016-08-18 Sanofi-Aventis Deutschland Gmbh Treatment of Pediatric Type 2 Diabetes Mellitus Patients
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Also Published As

Publication number Publication date
CR20170369A (es) 2017-11-01
HK1244701A1 (zh) 2018-08-17
NI201100068A (es) 2011-11-02
RS59913B1 (sr) 2020-03-31
CR20110188A (es) 2011-07-14
PA8845901A1 (es) 2010-05-26
MX2011003804A (es) 2011-05-02
JP2012505852A (ja) 2012-03-08
UY32183A (es) 2010-05-31
MA32703B1 (fr) 2011-10-02
CN102256618A (zh) 2011-11-23
CL2011000851A1 (es) 2012-07-20
CY1119952T1 (el) 2018-12-12
US10117909B2 (en) 2018-11-06
TW201026321A (en) 2010-07-16
SI3228320T1 (sl) 2020-03-31
EP2349324A2 (de) 2011-08-03
PT2349324T (pt) 2017-12-06
RS56632B1 (sr) 2018-03-30
MX344293B (es) 2016-12-13
BR122013025625A2 (pt) 2018-10-30
EP3677275B1 (de) 2024-06-12
EP2349324B1 (de) 2017-09-06
ES2650621T3 (es) 2018-01-19
PT3228320T (pt) 2020-03-26
KR20180008906A (ko) 2018-01-24
PE20120060A1 (es) 2012-02-23
HK1222568A1 (zh) 2017-07-07
ES2772731T3 (es) 2020-07-08
IL254465B (en) 2019-05-30
WO2010043566A3 (de) 2010-06-17
IL254465A0 (en) 2017-11-30
KR20160107351A (ko) 2016-09-13
HUE068164T2 (hu) 2024-12-28
BRPI0920881A2 (pt) 2017-09-26
ECSP11010986A (es) 2011-05-31
JP5732016B2 (ja) 2015-06-10
KR20110084956A (ko) 2011-07-26
BRPI0920881B1 (pt) 2021-09-21
CO6361944A2 (es) 2012-01-20
US20220016217A1 (en) 2022-01-20
BR122013025625B1 (pt) 2021-08-03
IL212258A (en) 2017-09-28
US20240108692A1 (en) 2024-04-04
DK3228320T3 (da) 2020-03-09
DK2349324T3 (en) 2017-12-11
TWI494121B (zh) 2015-08-01
US9526764B2 (en) 2016-12-27
AU2009305472B2 (en) 2013-12-19
CA3016451A1 (en) 2010-04-22
TN2011000160A1 (en) 2012-12-17
IL212258A0 (en) 2011-06-30
CN105396126A (zh) 2016-03-16
SI2349324T1 (en) 2018-01-31
RU2014132563A (ru) 2016-02-27
PL3677275T3 (pl) 2024-11-18
PT3677275T (pt) 2024-09-05
HN2011001021A (es) 2015-06-22
RU2011119639A (ru) 2012-11-27
CN103736082A (zh) 2014-04-23
WO2010043566A2 (de) 2010-04-22
HUE048608T2 (hu) 2020-08-28
EP3228320B1 (de) 2019-12-18
JP5731981B2 (ja) 2015-06-10
CA2740685A1 (en) 2010-04-22
EP3228320A1 (de) 2017-10-11
ZA201102400B (en) 2012-09-26
LT3228320T (lt) 2020-03-10
US20120021978A1 (en) 2012-01-26
CA2740685C (en) 2018-09-11
PL2349324T3 (pl) 2018-02-28
AU2009305472A1 (en) 2010-04-22
US20190192635A1 (en) 2019-06-27
KR101939557B1 (ko) 2019-01-17
HRP20171894T1 (hr) 2018-01-26
EP3677275A1 (de) 2020-07-08
RU2682671C2 (ru) 2019-03-20
ES2992698T3 (en) 2024-12-17
DOP2011000104A (es) 2011-05-15
PL3228320T3 (pl) 2020-06-01
KR101820024B1 (ko) 2018-01-18
LT2349324T (lt) 2017-12-27
US20170281733A1 (en) 2017-10-05
US20250161416A1 (en) 2025-05-22
JP2012255040A (ja) 2012-12-27
AR073872A1 (es) 2010-12-09
HUE037449T2 (hu) 2018-08-28
RU2532378C2 (ru) 2014-11-10
MX349717B (es) 2017-08-09
HRP20200340T1 (hr) 2020-06-12

Similar Documents

Publication Publication Date Title
NZ592283A (en) Combination of an insulin and the GLP-1 agonist AVE0010
Bajaj et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial
Jadzinsky et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
Hollander et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial
EA201590759A1 (ru) Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина
Perry et al. Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents
EA200870575A1 (ru) Композиции и способы лечения застойной сердечной недостаточности
MX2011007371A (es) Metodo para tratar la hiperglucemia con la molecula.
NO20084919L (no) Oksadiazolidindionforbindelse
MX366314B (es) Uso de derivados de insulina por inyecciones con intervalos variables.
BR112013032265A2 (pt) métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
MX2010004503A (es) Compuesto de oxadiazolidinediona.
BRPI0818687A2 (pt) composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
RU2012100397A (ru) Препарат, содержащий инсулин, никотинамид и аминокислоту
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
CY1113755T1 (el) Η λιξισενατιδη ως επιπροσθετη αγωγη στην ινσουλινη γλαργινη και στη μετφορμινη για τη θεραπευτικη αντιμετωπιση του διαβητη τυπου 2
Docsa et al. Insulin sensitivity is modified by a glycogen phosphorylase inhibitor: glucopyranosylidene-spiro-thiohydantoin in streptozotocin-induced diabetic rats
Cao et al. The clinical application of linagliptin in Asians
Bader et al. Vildagliptin more effectively achieves a composite endpoint of HbA1c< 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment
Woo A review of the clinical efficacy and safety of insulin degludec and glargine 300 U/mL in the treatment of diabetes mellitus
Zheng et al. Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver
JP2020502151A5 (enExample)
Heller et al. Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: A report from the Cardiac Safety Research Consortium
Mest Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement
WO2007076505A3 (en) Transferrin and transferrin-based compositions for diabetes treatment

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 OCT 2016 BY CPA GLOBAL

Effective date: 20130829

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2017 BY CPA GLOBAL

Effective date: 20160902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2018 BY CPA GLOBAL

Effective date: 20170831

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2019 BY CPA GLOBAL

Effective date: 20180830

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2020 BY CPA GLOBAL

Effective date: 20190829

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2021 BY CPA GLOBAL

Effective date: 20200903

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2022 BY CPA GLOBAL

Effective date: 20210902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2023 BY CPA GLOBAL

Effective date: 20220902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2024 BY CPA GLOBAL

Effective date: 20230831

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240829

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250904